ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project
ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, and Pionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will perform process development and GMP manufacturing on a second antibody from the Pionyr pipeline using their high performance CHO.RiGHT® expression platform. Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline, enabling a rapid advance to clinical trials.
“We developed a strong collaboration with Pionyr Immunotherapeutics on their initial antibody candidate, and we are enthusiastic about advancing a second antibody candidate into development. We consider Pionyr’s Myeloid Tuning™ approach to be ideally suited to target solid tumors and look forward to contributing to multiple programs with our CHO.RiGHT® development and manufacturing platform. We have established a seamless team working across the two companies and are very pleased to expand our collaboration”, said Dr René Brecht, VP Process Science and Manufacturing.
Evan Greger, Pionyr VP of Process Development and CMC, added, “Pionyr is developing a novel class of antibody-based therapeutics that can alter the tumor microenvironment to favor immune-activating cells over immune-suppressing cells. After establishing a collaboration with ProBioGen in 2017 to advance our first Myeloid Tuning™ candidate into cell line development and clinical trials, we are enthusiastic to continue our partnership and advance a second antibody candidate. ProBioGen is an outstanding partner with well-respected development and manufacturing services. The CHO.RiGHT® expression platform, combined with their experienced, committed team, is ideally suited for the rapid and successful advancement of our antibody programs into clinical trials.”
About ProBioGen AG
ProBioGen is a premier, Berlin-based specialist for development and manufacturing of complex therapeutic glycoproteins. Combining both state-of-the-art development platforms, based on its CHO.RIGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen was founded in 1994, is privately owned, and is located in Berlin, Germany.
About Pionyr Immunotherapeutics Inc.
Pionyr Immunotherapeutics (formerly Precision Immune Inc.), located in San Francisco, California, USA, is developing cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create a next generation of immuno-oncology therapeutics. The company's approach, Myeloid Tuning™, is designed to enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity. Pionyr’s Myeloid Tuning™ technology is based on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.
Vice President, Process Development and CMC
Pionyr Immunotherapeutics Inc.
953 Indiana Street
San Francisco, CA 94107
+1 415 226 7503